[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606477":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":40,"responsibleParty":60,"collaborators":26,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":26,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":26,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":92,"whyStopped":26,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"University of Malaya","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ropivacaine + Saline","ACTIVE_COMPARATOR","Patients will receive 20 mL of periarticular infiltration consisting of 19 mL of 0.5% ropivacaine and 1 mL of normal saline during total knee replacement.",[13],"Drug: Ropivacaine + saline solution",{"label":15,"type":16,"description":17,"interventionNames":18},"Ropivacaine + Dexmedetomidine","EXPERIMENTAL","Patients will receive 20 mL of periarticular infiltration consisting of 19 mL of 0.5% ropivacaine and 100 µg dexmedetomidine in 1 mL during total knee replacement.",[19],"Drug: Ropivacaine + Dexmedetomidine",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Ropivacaine + saline solution","0.5% ropivacaine (19 mL) + 1 mL normal saline administered intraoperatively via periarticular injection.",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"0.5% ropivacaine (19 mL) + dexmedetomidine 100 µg in 1 mL administered intraoperatively via periarticular injection.",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Ahmad Fariz Elias, MD","CONTACT","+60194062520","fariz_elias@ummc.edu.my",{"name":37,"role":33,"phone":38,"phoneExt":26,"email":39},"Ahmad Abid Amin, MBBS","+60133131064","abid.amin@ummc.edu.my",[41],{"facility":42,"status":26,"city":43,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Universiti Malaya Medical Centre","Kuala Lumpur","59100","Malaysia","MY",{"type":48,"coordinates":49},"Point",[50,51],101.68653,3.1412,{"lat":51,"lon":50},[54,55,57],{"name":37,"role":33,"phone":38,"phoneExt":26,"email":39},{"name":32,"role":56,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"name":58,"role":59,"phone":26,"phoneExt":26,"email":26},"Nabilah Abdul Ghani, MD","SUB_INVESTIGATOR",{"type":56,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Ahmad Fariz Bin Elias","Clinical specialist","100606477","phase-4-dexmedetomidine-as-an-adjunct-to-periarticular-ropivacaine-in-total-knee-replacement-a-pilot-randomised-controlled-trial-100606477",false,"NCT07176065","Dexmedetomidine as an Adjunct to Periarticular Ropivacaine in Total Knee Replacement: A Pilot Randomised Controlled Trial","A Pilot Randomized Controlled Trial Assessing the Impact of Dexmedetomidine as an Adjunct to Periarticular Ropivacaine Infiltration on Postoperative Pain and Recovery in Patients Undergoing Total Knee Replacement","Inclusion Criteria:\n\n* Aged ≥18 years\n* Undergoing elective unilateral total knee replacement\n* ASA physical status I-III\n* No known allergy to local anaesthetics or dexmedetomidine\n* No opioid use \\>24 hours preoperatively\n* Provided informed consent\n\nExclusion Criteria:\n\n* Known allergy to study drugs\n* Chronic pain or neurological conditions\n* Bilateral or revision TKR\n* Significant deformity affecting function\n* Substance abuse history\n* Day-case surgery","ALL","18 Years","100 Years",{"count":74,"type":75},60,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","This study aims to evaluate whether adding dexmedetomidine to ropivacaine-based periarticular infiltration (PAI) improves postoperative pain control in patients undergoing total knee replacement (TKR). Despite standard pain management, many patients continue to experience moderate-to-severe pain after surgery. Dexmedetomidine, a sedative and analgesic agent, may help prolong the effect of local anaesthetics. A total of 60 patients will be randomly assigned to receive either ropivacaine alone or ropivacaine with dexmedetomidine. Pain scores, opioid use, side effects, and recovery time will be monitored for 24 hours. The goal is to determine if this method is more effective and safer for improving recovery after knee surgery.",[81],"Postoperative Pain Management in Total Knee Arthroplasty",[83,84,85,86,87,88,89,90,91],"Total Knee Replacement","TKR","Periarticular Infiltration","Ropivacaine","Dexmedetomidine","Postoperative Pain","Opioid Consumption","Regional Anaesthesia","Adductor Canal Block","NOT_YET_RECRUITING","2025-09-08",{"date":95,"type":96},"2025-09-16","ACTUAL",{"date":98,"type":75},"2025-10",{"date":100,"type":75},"2028-12",{"name":5,"class":6},1]